Literature DB >> 30087522

Hepatorenal Syndrome: Physiology, Diagnosis and Management.

Joseph Chmielewski1, Robert J Lewandowski2,3,4, Haripriya Maddur5.   

Abstract

Individuals with end-stage liver disease are susceptible to a myriad of highly morbid complications, including hepatorenal syndrome (HRS). This specific type of renal dysfunction in patients with underlying liver disease occurs in pathophysiologically normal kidneys and is a result of renal vasoconstriction secondary to diminished renal blood flow in the setting of worsening hepatic dysfunction. Liver transplantation is curative; shortage of available organs limits access to this beneficial therapy. Medical management of HRS has demonstrated increasing promise. Transjugular intrahepatic portosystemic shunt creation has also been shown to be efficacious in enhancing transplant-free survival, although further study is advisable before widespread implementation of this strategy.

Entities:  

Keywords:  TIPS; hepatorenal syndrome; pathophysiology; terlipressin

Year:  2018        PMID: 30087522      PMCID: PMC6078701          DOI: 10.1055/s-0038-1660797

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN: 0739-9529            Impact factor:   1.513


  20 in total

Review 1.  Hepatorenal syndrome: Update on diagnosis and treatment.

Authors:  Olga Baraldi; Chiara Valentini; Gabriele Donati; Giorgia Comai; Vania Cuna; Irene Capelli; Maria Laura Angelini; Maria Ilaria Moretti; Andrea Angeletti; Fabio Piscaglia; Gaetano La Manna
Journal:  World J Nephrol       Date:  2015-11-06

Review 2.  Hepatorenal syndrome: pathophysiology and management.

Authors:  Hani M Wadei; Martin L Mai; Nasimul Ahsan; Thomas A Gonwa
Journal:  Clin J Am Soc Nephrol       Date:  2006-07-12       Impact factor: 8.237

3.  Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis.

Authors:  F Keller; H Heinze; F Jochimsen; J Passfall; D Schuppan; P Büttner
Journal:  Ren Fail       Date:  1995-03       Impact factor: 2.606

4.  Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites.

Authors:  Paolo Angeli; Pere Ginès; Florence Wong; Mauro Bernardi; Thomas D Boyer; Alexander Gerbes; Richard Moreau; Rajiv Jalan; Shiv K Sarin; Salvatore Piano; Kevin Moore; Samuel S Lee; Francois Durand; Francesco Salerno; Paolo Caraceni; W Ray Kim; Vicente Arroyo; Guadalupe Garcia-Tsao
Journal:  J Hepatol       Date:  2015-01-28       Impact factor: 25.083

5.  Dialysis in the treatment of renal failure in patients with liver disease.

Authors:  S P Wilkinson; M J Weston; V Parsons; R Williams
Journal:  Clin Nephrol       Date:  1977-07       Impact factor: 0.975

6.  Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functionalnature of renal failure in advanced liver disease.

Authors:  M H Koppel; J W Coburn; M M Mims; H Goldstein; J D Boyle; M E Rubini
Journal:  N Engl J Med       Date:  1969-06-19       Impact factor: 91.245

Review 7.  Hepatorenal syndrome.

Authors:  Pere Ginès; Mónica Guevara; Vicente Arroyo; Juan Rodés
Journal:  Lancet       Date:  2003-11-29       Impact factor: 79.321

Review 8.  TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis.

Authors:  Ming Bai; Xing-Shun Qi; Zhi-Ping Yang; Man Yang; Dai-Ming Fan; Guo-Hong Han
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

Review 9.  Hepatorenal syndrome: emerging perspectives of pathophysiology and therapy.

Authors:  M Epstein
Journal:  J Am Soc Nephrol       Date:  1994-04       Impact factor: 10.121

10.  Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.

Authors:  A J Sanyal; T D Boyer; R T Frederick; F Wong; L Rossaro; V Araya; H E Vargas; K R Reddy; S C Pappas; P Teuber; S Escalante; K Jamil
Journal:  Aliment Pharmacol Ther       Date:  2017-03-29       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.